STOCK TITAN

Doximity (DOCS) Financials

DOCS NYSE
FY2026 annual
Revenue $644.9M +13.1% YoY
Net Income $196.1M -12.2% YoY
EPS (Diluted) $0.98 -11.7% YoY
Free Cash Flow $326.5M +19.5% YoY
Market Cap $5.6B as of Nov 17, 2026
Price / Sales 8.4x on $661.6M revenue, trailing 12 months to September 30, 2026
Price / Earnings 39.7x on $139.7M net income, trailing 12 months to September 30, 2026
Price / Book 6.0x on $928.5M equity, Q2 FY2027

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2027, ended Sep 30, 2026 Reported Currency USD FYE March

Newest figures come from the 10-Q for Q2 FY2027, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DOCS SEC filings page.

Doximity, Inc. (DOCS) reported $644.9M in revenue for fiscal year 2026, up 13.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI DOCS FY2026

Doximity remains highly cash-generative, but FY2026 growth was absorbed by heavier investment and shareholder distributions rather than operating profit.

FY2026 paired a 12.2% net-income decline with 19.5% free-cash-flow growth, an unusual divergence that makes cash generation look healthier than accounting earnings. Operating cash flow reached 166.5% of net income versus 122.4% in FY2025, so the earnings-to-cash relationship strengthened materially.

Revenue grew 13.1%, yet operating income fell 5.7%, showing incremental sales did not translate into operating profit. R&D rose from 16.3% to 20.3% of revenue, indicating heavier reinvestment as the near-term tradeoff.

Liabilities were 15.4% of assets and the current ratio was 6.1x, indicating a balance sheet not dependent on heavy obligations for day-to-day funding. Buybacks totaled $431.7M against free cash flow of $326.5M, so distributions exceeded internally generated cash in FY2026.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 89 / 100
Financial Health Score 89/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Doximity, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
93

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Doximity, Inc. scores 93/100 on it among other operating companies.

Growth
78

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Doximity, Inc. scores 78/100 on it among other operating companies.

Leverage
83

Doximity, Inc. carried $0.18 of total liabilities for every $1 of shareholders' equity at the end of fiscal year 2026. With no long-term debt figure for fiscal year 2026, Doximity, Inc. is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 83/100 among other operating companies measured the same way.

Liquidity
94

Doximity, Inc. held $6.09 of current assets for every $1 of current liabilities at the end of fiscal year 2026, a current ratio of 6.09. Liquidity ranks operating companies on that ratio, and Doximity, Inc. scores 94/100 among other operating companies.

Cash Flow
98

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Doximity, Inc. scores 98/100 on it among other operating companies.

Returns
86

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Doximity, Inc. scores 86/100 on it among other operating companies.

Altman Z-Score Safe
21.25

Doximity, Inc. scores 21.25, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $5.6B against total liabilities of $172.8M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
5/8

Doximity, Inc. passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality Cash-Backed
1.67x

For every $1 of reported earnings, Doximity, Inc. generates $1.67 in operating cash flow ($326.5M OCF vs $196.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$174.5M
YoY+3.6%
QoQ+11.4%
5Y CAGR+17.1%

Doximity, Inc. generated $174.5M in revenue in Q2 2027. This represents an increase of 3.6% from the same quarter a year earlier. Against the prior quarter it is up 11.4%.

EBITDA
$48.3M
YoY-28.1%
QoQ+27.3%
5Y CAGR+13.1%

Doximity, Inc.'s EBITDA was $48.3M in Q2 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 28.1% from the same quarter a year earlier. Against the prior quarter it is up 27.3%.

Net Income
$34.7M
YoY-44.0%
QoQ+42.8%
5Y CAGR-0.8%

Doximity, Inc. reported $34.7M in net income in Q2 2027. This represents a decrease of 44.0% from the same quarter a year earlier. Against the prior quarter it is up 42.8%.

EPS (Diluted)
$0.18
YoY-41.9%
QoQ+38.5%
5Y CAGR+1.1%

Doximity, Inc. earned $0.18 per diluted share (EPS) in Q2 2027. This represents a decrease of 41.9% from the same quarter a year earlier. Against the prior quarter it is up 38.5%.

Cash & Balance Sheet

Free Cash Flow
$93.3M
YoY-0.7%
QoQ+122.5%

Doximity, Inc. generated $93.3M in free cash flow in Q2 2027, representing cash available after capex. This represents a decrease of 0.7% from the same quarter a year earlier. Against the prior quarter it is up 122.5%.

Cash & Debt
$218.6M
YoY+29.2%
QoQ-20.1%
5Y CAGR+22.4%

Doximity, Inc. held $218.6M in cash as of Q2 2027; no long-term debt figure is on record for that period.

Shares Outstanding
178M
YoY-5.2%
QoQ-0.8%
5Y CAGR-0.9%

Doximity, Inc. had 178M shares outstanding in Q2 2027. This represents a decrease of 5.2% from the same quarter a year earlier. Against the prior quarter it is down 0.8%.

Dividends Per Share

Not reported for Q2 2027.

Margins & Returns

Gross Margin
85.5%
YoY-4.8pp
QoQ+0.6pp
5Y change-3.2pp

Doximity, Inc.'s gross margin was 85.5% in Q2 2027, indicating the percentage of revenue retained after direct costs. This is down 4.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.6 percentage points.

Operating Margin
25.2%
YoY-12.6pp
QoQ+3.7pp
5Y change-6.3pp

Doximity, Inc.'s operating margin was 25.2% in Q2 2027, reflecting core business profitability. This is down 12.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.7 percentage points.

Net Margin
19.9%
YoY-16.9pp
QoQ+4.4pp
5Y change-25.6pp

Doximity, Inc.'s net profit margin was 19.9% in Q2 2027, showing the share of revenue converted to profit. This is down 16.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.4 percentage points.

Return on Equity
3.7%
YoY-1.9pp
QoQ+1.1pp
5Y change-0.9pp

Doximity, Inc.'s quarterly ROE was 3.7% in Q2 2027: one quarter's net income over shareholder equity, not annualized. This is down 1.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.

Capital Allocation

R&D Spending
$42.0M
YoY+38.9%
QoQ+9.1%
5Y CAGR+22.1%

Doximity, Inc. invested $42.0M in research and development in Q2 2027. This represents an increase of 38.9% from the same quarter a year earlier. Against the prior quarter it is up 9.1%.

Share Buybacks
$54.2M
YoY+147.6%
QoQ-40.9%
5Y CAGRn/m

Doximity, Inc. spent $54.2M on share buybacks in Q2 2027, returning capital to shareholders by reducing shares outstanding. This represents an increase of 147.6% from the same quarter a year earlier. Against the prior quarter it is down 40.9%.

Capital Expenditures
$0
YoYn/m
QoQ-100.0%

Doximity, Inc. reported no capital expenditure in Q2 2027. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 100.0%.

DOCS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DOCS quarterly income statement
MetricQ2'2710-QQ1'2710-QQ4'2610-KQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-Q
Revenue$174.5M+3.6%$156.6M+7.3%$145.4M+5.1%$185.1M+9.8%$168.5M+23.2%$145.9M+15.2%$138.3M+17.1%$168.6M+24.6%
Cost of Revenue$25.3M+54.3%$23.7M+50.0%$19.4M+34.1%$18.7M+31.9%$16.4M+20.1%$15.8M+16.6%$14.5M+15.1%$14.2M+16.3%
Gross Profit$149.2M-1.9%$132.9M+2.2%$126.0M+1.7%$166.4M+7.7%$152.1M+23.5%$130.1M+15.0%$123.8M+17.4%$154.4M+25.5%
R&D Expenses$42.0M+38.9%$38.5M+43.6%$39.1M+57.7%$34.6M+54.3%$30.2M+30.0%$26.8M+18.7%$24.8M+23.1%$22.4M+12.4%
SG&A Expenses$63.3M+8.7%$60.8M+24.6%$62.0M+23.2%$59.9M+14.9%$58.2M+30.9%$48.8M+9.7%$50.3M+15.7%$52.1M+16.8%
Operating Income$43.9M-31.0%$33.6M-38.3%$24.8M-49.0%$71.9M-10.0%$63.7M+19.8%$54.5M+18.4%$48.7M+16.3%$79.9M+36.5%
EBITDA$48.3M-28.1%$37.9M-33.8%$29.0M-43.8%$75.9M-8.1%$67.2M+20.4%$57.3M+17.9%$51.5M+16.0%$82.6M+35.2%
Income Tax$15.6M+43.4%$16.0M+48.2%$13.0Mn/m$19.2M+31.4%$10.9M-39.6%$10.8M-8.2%-$4.1M-155.4%$14.6M-2.9%
Net Income$34.7M-44.0%$24.3M-54.4%$19.1M-69.4%$61.6M-18.1%$62.1M+40.6%$53.3M+28.9%$62.5M+53.8%$75.2M+56.8%
EPS (Basic)$0.19-42.4%$0.13-53.6%$0.11-66.7%$0.33-17.5%$0.33+37.5%$0.28+27.3%$0.33+50.0%$0.40+53.8%
EPS (Diluted)$0.18-41.9%$0.13-51.9%$0.10-67.7%$0.31-16.2%$0.31+40.9%$0.27+28.6%$0.31+55.0%$0.37+54.2%
Diluted Shares (Avg)188M-6.4%191M-5.0%N/A199M-1.5%201M+0.2%201M+1.0%N/A202M+0.9%

Not reported in any period shown, so not listed: Interest Expense.

DOCS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DOCS quarterly balance sheet
MetricQ2'2710-QQ1'2710-QQ4'2610-KQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-Q
Total Assets$1.1B-13.2%$1.1B-10.0%$1.1B-11.1%$1.2B-1.3%$1.3B+12.4%$1.2B+12.2%$1.3B+17.1%$1.2B+17.1%
Current Assets$921.5M-15.6%$914.0M-11.6%$944.3M-13.3%$993.5M-1.9%$1.1B+14.0%$1.0B+13.8%$1.1B+19.2%$1.0B+20.4%
Cash & Equivalents$218.6M+29.2%$273.6M+99.3%$219.2M+4.6%$64.8M-60.8%$169.2M-8.1%$137.3M+23.2%$209.6M+116.6%$165.3M+34.3%
Short-Term Investments$494.6M-30.2%$414.2M-41.1%$529.4M-25.0%$670.3M-1.4%$709.1M+14.1%$703.7M+10.1%$706.0M+6.0%$679.7M+15.8%
Accounts Receivable$166.1M+28.5%$177.6M+25.4%$144.8M+12.8%$156.6M+13.9%$129.3M+3.6%$141.7M+17.2%$128.4M+26.7%$137.5M+40.9%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$85.0M0.0%$85.0M+25.1%$85.0M+25.1%$85.0M+25.1%$85.0M+25.1%$67.9M0.0%$67.9M0.0%$67.9M0.0%
Total Liabilities$163.3M+1.1%$167.8M-6.2%$172.8M-4.9%$177.7M+26.0%$161.6M+2.7%$178.9M+11.9%$181.7M+2.1%$141.0M+3.7%
Current Liabilities$144.6M+3.1%$150.4M-6.0%$155.0M-0.8%$149.8M+29.3%$140.3M+6.0%$159.9M+18.2%$156.3M+6.1%$115.9M+10.6%
Non-Current Liabilities$18.7M-12.3%$17.4M-8.1%$17.9M-29.7%$27.9M+10.8%$21.3M-14.9%$18.9M-23.0%$25.4M-17.2%$25.2M-19.6%
Total Equity$928.5M-15.2%$916.1M-10.7%$950.8M-12.2%$979.3M-5.0%$1.1B+14.0%$1.0B+12.3%$1.1B+20.1%$1.0B+19.3%
Retained Earnings-$138.7M-188.0%-$119.0M-201.7%-$51.1M-127.3%$21.0M-86.1%$157.7M+65.6%$117.1M+60.6%$186.9M+133.6%$151.2M+147.9%

Not reported in any period shown, so not listed: Inventory, Long-Term Debt.

DOCS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DOCS quarterly cash flow statement
MetricQ2'2710-QQ1'2710-QQ4'2610-KQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-Q
Operating Cash Flow$93.3M-0.7%$42.0M-32.4%$109.5M+11.2%$60.9M-6.6%$93.9M+37.5%$62.1M+50.6%$98.5M+54.0%$65.2M+30.2%
Depreciation & Amortization$4.4M+25.5%$4.3M+53.4%$4.1M+46.0%$4.0M+50.2%$3.5M+32.8%$2.8M+9.1%$2.8M+11.0%$2.7M+5.8%
Stock-Based Compensation$40.6M+37.6%$36.8M+68.1%N/A$33.5M+73.2%$29.5M+65.0%$21.9M+27.9%N/A$19.4M+64.5%
Capital Expenditures$0n/m$62Kn/mN/AN/A$0n/m$0n/m$0n/m$0-100.0%
Free Cash Flow$93.3M-0.7%$41.9M-32.5%N/AN/A$93.9M+37.5%$62.1M+50.6%$98.5M+54.0%$65.2M+30.3%
Investing Cash Flow-$84.0Mn/m$113.0M+4117.6%$138.0Mn/m$38.2Mn/m-$31.7M-231.3%$2.7M-91.1%-$24.5Mn/m-$58.9M-246.8%
Financing Cash Flow-$64.2Mn/m-$100.6Mn/m-$93.2Mn/m-$203.5Mn/m-$30.2Mn/m-$137.1Mn/m-$29.7Mn/m-$25.2Mn/m
Share Buybacks$54.2M+147.6%$91.6M-25.1%$90.5M+237.9%$196.9M+919.7%$21.9M-4.7%$122.4M+138.9%$26.8M+51.0%$19.3M-74.9%

Not reported in any period shown, so not listed: Dividends Paid.

DOCS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

DOCS quarterly financial ratios
MetricQ2'2710-QQ1'2710-QQ4'2610-KQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-Q
Gross Margin85.5%-4.8pp84.9%-4.3pp86.7%-2.9pp89.9%-1.7pp90.3%+0.2pp89.2%-0.1pp89.5%+0.2pp91.6%+0.6pp
Operating Margin25.2%-12.6pp21.5%-15.9pp17.1%-18.1pp38.9%-8.5pp37.8%-1.1pp37.4%+1.0pp35.2%-0.3pp47.4%+4.1pp
Net Margin19.9%-16.9pp15.5%-21.0pp13.2%-32.0pp33.3%-11.3pp36.8%+4.6pp36.5%+3.9pp45.2%+10.8pp44.6%+9.2pp
Return on Equity3.7%-1.9pp2.6%-2.5pp2.0%-3.8pp6.3%-1.0pp5.7%+1.1pp5.2%+0.7pp5.8%+1.3pp7.3%+1.7pp
Return on Assets3.2%-1.8pp2.2%-2.2pp1.7%-3.2pp5.3%-1.1pp4.9%+1.0pp4.4%+0.6pp4.9%+1.2pp6.4%+1.6pp
Current Ratio6.37-1.4x6.08-0.4x6.09-0.9x6.63-2.1x7.79+0.5x6.47-0.2x6.97+0.8x8.74+0.7x
Liabilities-to-Equity0.180.0x0.180.0x0.180.0x0.180.0x0.150.0x0.170.0x0.170.0x0.140.0x
Asset Turnover0.160.0x0.140.0x0.130.0x0.160.0x0.130.0x0.120.0x0.110.0x0.140.0x
FCF Margin53.4%-2.3pp26.8%-15.8ppN/AN/A55.7%+5.8pp42.6%+10.0pp71.2%+17.1pp38.7%+1.7pp

Not reported in any period shown, so not listed: Debt-to-Equity.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Doximity, Inc. DOCS FY2026 $644.9M $196.1M 30.4% $5.6B 89/100
Waystar Holding Corp. WAY FY2025 $1.1B $112.1M 10.2% $5.3B 60/100
HealthEquity, Inc HQY FY2026 $1.3B $215.2M 16.4% $8.4B 70/100
Heartflow, Inc. HTFL FY2025 $176.0M -$116.8M -66.3% $4.1B 61/100
Hinge Health, Inc. HNGE FY2025 $587.9M -$528.3M -89.9% $9.3B 80/100
Privia Health Group, Inc. PRVA FY2025 $2.1B $22.9M 1.1% $3.2B 44/100

Frequently Asked Questions

Doximity, Inc. (DOCS) reported $644.9M in total revenue for fiscal year 2026. This represents a 13.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Doximity, Inc. (DOCS) revenue grew by 13.1% year-over-year, from $570.4M to $644.9M in fiscal year 2026.

Yes, Doximity, Inc. (DOCS) reported a net income of $196.1M in fiscal year 2026, with a net profit margin of 30.4%.

Doximity, Inc. (DOCS) reported diluted earnings per share of $0.98 for fiscal year 2026. This represents a -11.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Doximity, Inc. (DOCS) had EBITDA of $229.3M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

Doximity, Inc. (DOCS) had a gross margin of 89.1% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

Doximity, Inc. (DOCS) had an operating margin of 33.3% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

Doximity, Inc. (DOCS) had a net profit margin of 30.4% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

Doximity, Inc. (DOCS) has a return on equity of 20.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

Doximity, Inc. (DOCS) generated $326.5M in free cash flow during fiscal year 2026. This represents a 19.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Doximity, Inc. (DOCS) generated $326.5M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

Doximity, Inc. (DOCS) had $1.1B in total assets as of fiscal year 2026, including both current and long-term assets.

Doximity, Inc. (DOCS) reported no capital expenditure during fiscal year 2026.

Doximity, Inc. (DOCS) invested $130.7M in research and development during fiscal year 2026.

Yes, Doximity, Inc. (DOCS) spent $431.7M on share buybacks during fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

Doximity, Inc. (DOCS) had 183M shares outstanding as of fiscal year 2026.

Doximity, Inc. (DOCS) had a current ratio of 6.09 as of fiscal year 2026, which is generally considered healthy.

Doximity, Inc. (DOCS) had a liabilities-to-equity ratio of 0.18 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.

Doximity, Inc. (DOCS) had a return on assets of 17.4% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

Doximity, Inc. (DOCS) trades at 39.7x earnings, its market capitalization divided by $139.7M net income, trailing 12 months to September 30, 2026. The market capitalization is $5.6B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Doximity, Inc. (DOCS) trades at 8.4x sales, its market capitalization divided by $661.6M revenue, trailing 12 months to September 30, 2026. The market capitalization is $5.6B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Doximity, Inc. (DOCS) has an Altman Z-Score of 21.25, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Doximity, Inc. (DOCS) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Doximity, Inc. (DOCS) has an earnings quality ratio of 1.67x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Doximity, Inc. (DOCS) scores 89 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top